An early assessment of the EU’s pilot program for monitoring and reporting drug safety information has shown that the initiative has pharmaceutical industry backing but that companies have concerns about how it is operating.
At a meeting with the European Medicines Agency in March, industry representatives said that they supported the proposed metrics for evaluating the pilot and were happy to collaborate on data...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?